Video Shorts

Alexander Drilon, MD
0:53
Alexander Drilon, MD, Discusses Human Touch in Cancer Care
3 days ago
by
Alexander Drilon, MD
Byoung Chul Cho, MD, PhD
0:53
Learning Korean at BTG Lung in Seoul!
5 days ago
by
Byoung Chul Cho, MD, PhD
Chris Grant, MD
1:35
What's One Thing Your Patients Have Taught You?
6 days ago
by
Chris Grant, MD
WCLC 2026
1:44
Human Touch in Cancer Care
7 days ago
by
Riley Kandel(+1 more)
SOHO 2026
1:38
SOHO 2026 RECAP
8 days ago
by
Riley Kandel(+1 more)
Stephen V. Liu, MD
1:04
Treatment for Locally Advanced Stage IIIA, ALK+ NSCLC
8 days ago
by
Stephen Liu, MD
On an episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, and Karine Tawagi, MD, summarize best practices for early-stage and locally advanced non–small cell lung cancer staging and management.
1:16
Spotlighting Best Practices for NSCLC Staging and Management
9 days ago
by
Karine Tawagi, MD(+1 more)
On an episode of Breast Cancer Briefing, guest Dana Bonaminio, MD, shares why individualized breast cancer risk assessment should determine when a patient's first mammogram happens.
1:14
Highlighting the Importance of Individualized Breast Cancer Screening Practices
9 days ago
by
Sara Nunnery, MD, MSCI(+1 more)
Andrew Kuykendall, MD, of Moffitt Cancer Center, ranks novel MPN treatments at the 2026 SOHO Annual Meeting.
2:18
Ranking Novel MPN Treatments at SOHO 2026
9 days ago
by
Andrew Kuykendall, MD(+1 more)
Catch OncLive On the Ground at SOHO and WCLC 2026!
0:26
Catch OncLive On the Ground at SOHO and WCLC 2026!
11 days ago
by
Riley Kandel
Charles E. Geyer, MD
1:20
Noting ILD/Radiation Pneumonitis Outcomes From DESTINY-Breast05
17 days ago
by
Charles E. Geyer, MD
Chronic Neutropenia
1:13
Exploring Mavorixafor in Chronic Neutropenia Management
18 days ago
by
David Sykes, MD, PhD
Aaron Gerds, MD, MS, breaks down considerations for selecting a JAK inhibitor in the treatment of patients with myelofibrosis.
1:33
Selecting a JAK Inhibitor in Myelofibrosis
18 days ago
by
Aaron Gerds, MD, MS
Midhun Malla, MD
1:36
Spotlighting the Importance of Biomarker Testing in GI Cancer
19 days ago
by
Midhun Malla, MD
Philip A. Philip, MD
1:38
Highlighting Appendix Cancer Awareness Month
19 days ago
by
Philip A. Philip, MD
Ranee Mehra, MD
1:01
Examining Amivantamab in Head and Neck Cancer
20 days ago
by
Ranee Mehra, MD
Zulfa Omer, MD
0:41
Comparing Mechanisms of Action for BTK Degraders and Inhibitors
23 days ago
by
Zulfa Omer, MD
Alan L. Ho, MD, PhD
1:19
Highlighting a Phase 3 Trial of Ozuriftamab Vedotin in HPV-Associated OPSCC
23 days ago
by
Alan L. Ho, MD, PhD
Breast Cancer Briefing
0:52
Individualizing Efforts to Lower Recurrence Risk in Breast Cancer
23 days ago
by
Sara Nunnery, MD, MSCI(+1 more)
Uma Borate, MBBS, MS
1:13
Unpacking Data for Shorter Venetoclax Schedules in AML
23 days ago
by
Uma Borate, MBBS, MS
Andrew E. Hendifar, MD
1:15
Highlighting Radioligand Therapies in GEP-NETs
24 days ago
by
Andrew E. Hendifar, MD
Fangdi Sun, MD
0:47
Emphasizing the Importance of Biomarkers in Head and Neck Cancer
24 days ago
by
Fangdi Sun, MD
Daniel H. Ahn, DO
0:39
Spotlighting the Efficacy and Safety of Atebimetinib-Based Therapy in Pancreatic Cancer
24 days ago
by
Daniel H. Ahn, DO
Andrew H. Ko, MD
0:51
How Does Optune Pax Work in Pancreatic Cancer?
24 days ago
by
Andrew Ko, MD
Shubham Pant, MD, MBBS
0:45
Highlighting the Efficacy of Daraxonrasib in Pancreatic Cancer
24 days ago
by
Shubham Pant, MD, MBBS
Dan P Zandberg, MD
0:46
Exploring Unmet Needs in Head and Neck Cancer
25 days ago
by
Dan Zandberg, MD
Kim A. Reiss Binder, MD
1:30
What Is the Mechanism of Action of the Newly Approved Daraxonrasib for PDAC?
25 days ago
by
Kim A. Reiss Binder, MD
Adanma Ayanambakkam, MD, MS
1:05
What Are the Next Steps for Darlifarnib Plus Cabozantinib in RCC?
a month ago
by
Adanma Ayanambakkam, MD, MS
Zev A. Wainberg, MD
1:00
Predicting How Today's FDA Approval of Zanidatamab Will Affect Gastric Cancer Care
a month ago
by
Zev A. Wainberg, MD
Paul E. Oberstein, MD
0:43
What Does the RASolute 302 Trial Mean for Pancreatic Cancer Care?
a month ago
by
Paul E. Oberstein, MD